Change in oxcarbazepine (Trileptal®) formulation is associated with more side effects and higher blood concentrations [4]

Journal of Neurology Neurosurgery and Psychiatry

Volumn 71, Issue 5, 2001, Pages 708-709

  Edelbroek, P M ^a   Augustijn, P B ^a   De Haan, G J ^a   Rademaker, M V ^a   Geesink, H H ^a  

^a Dutch Epilepsy Clinics Foundation   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

OXCARBAZEPINE;

ATAXIA; DIPLOPIA; DRUG APPROVAL; DRUG BLOOD LEVEL; DRUG FORMULATION; DRUG HALF LIFE; DRUG SAFETY; DRUG TOLERABILITY; DYSARTHRIA; EPILEPSY; HUMAN; LETTER; NETHERLANDS; PRIORITY JOURNAL; UNITED KINGDOM; UNITED STATES; VERTIGO;

ANTICONVULSANTS; CARBAMAZEPINE; EPILEPSY; HUMANS;

EID: 0034771061     PISSN: 00223050     EISSN: None     Source Type: Journal    
DOI: 10.1136/jnnp.71.5.708     Document Type: Letter

References (5)

1. New drug treatments for epilepsy
2. Oxcarbazepine (GP 47.680): A possible alternative to carbamazepine?
3. Oxcarbazepine: A review of its pharmacology and therapeutic potential in epilepsy, trigeminal neuralgia and affective disorders
4. Oxcarbazepine: A review
5. Fluctuations of 10-hydroxy-carbazepine during the day in epileptic patients